Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder

NCT00100776 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00100776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2003
Completion date
November 30, 2005
Enrollment
600
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia